Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Dr. Dölen presents evidence linking psychedelics to reopening the social reward learning critical period, suggesting a shared mechanism across these drugs. This metaplastic restoration of oxytocin-mediated long-term depression may have
Psychedelics elevate neural activity, engage neural plasticity, and may relieve depression, anxiety, or addiction symptoms. Research focuses on neuron types and plasticity mechanisms in the prefrontal cortex.
Andrea Gomez
Manoj Doss discusses psychedelic impact on episodic memories, highlighting FLUX theory. Fred Barrett explores psychedelic therapy's potential for lasting shifts in psychological and cognitive flexibility across disorders.
Frederick Barrett, Manoj K. Doss
DMT and 5-MeO-DMT induce profound experiences, including encounters with entities and shifts in beliefs. Imperial College London's research investigates these psychedelics' effects on the brain and consciousness for therapeutic insights.
Clinical trials show potential of psychedelics for psychiatric treatment, but studies note varied responses. Unclear clinical mechanism discussed in talk on neurobiology and optimizing psychedelic therapy.